human igg1 fab lambda (Bethyl)

Bethyl is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bethyl human igg1 fab lambda
Human Igg1 Fab Lambda, supplied by Bethyl, used in various techniques. Bioz Stars score: 94/100, based on 279 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igg1+fab+lambda/Human+IgG-Fab+Antibody/pmc03187242-74-39-45
Average 94 stars, based on 279 article reviews

human igg1 fab lambda - by Bioz Stars, 2026-10

94/100 stars

Images

Expressing:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 μg/ml of human or mouse IgG (Sigma-Aldrich), 10 μg/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 μg/ml of human or mouse IgA (Sigma-Aldrich), 10 μg/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 μg/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 μg/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 μg/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 μg/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 μg/ml of human IgG for 2 h at 37°C..

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Derivative Assay:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Construct:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Sequencing:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Residue:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Clone Assay:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Introduce:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Conjugation Assay:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

SDS Page:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Clear Native PAGE:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Size-exclusion Chromatography:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Staining:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Western Blot:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Marker:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Membrane:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Generated:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Enzyme-linked Immunosorbent Assay:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Immunopeptidomics:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Adjuvant:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Control:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

MANN-WHITNEY:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Infection:

Article Title: Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development
Article Snippet: Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.Using essentially the same human IgG-ELISA protocol as that described above, the affinity of the COMP-Z delivery molecule for various human or mouse Igs was evaluated.. The Igs used as capture antigens were 5 g/ml of human or mouse IgG (Sigma-Aldrich), 10 g/ml of human (Sigma-Aldrich) or mouse (Bethyl Laboratories Inc., Montgomery, TX) IgM, 10 g/ml of human or mouse IgA (Sigma-Aldrich), 10 g/ml of human IgG1 Fab lambda or kappa (Bethyl Laboratories Inc.), or 10 g/ml of mouse IgG Fab (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).. After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C to mask unbound free Z domains.After the plate was blocked with 1% BSA in PBS, the COMP-Z or COMP (2 g/well each) was applied and incubated for 2 h at 37°C, followed by incubation with 5 g/ml of human IgG for 2 h at 37°C..

Review